medigraphic.com
ISSN 1561-302X (Print)

2021, Number 2

<< Back Next >>

Rev cubana med 2021; 60 (2)

Rapid desensitization protocol in patients with moderate to severe hypersensitivity reaction to cytostatics

Soriano GJL, Lima PM, Amón CI, Caballero AI, Artiles MAJ, Fuentes CLA, Hernández GY, Fleites LIN

Language: Spanish
References: 30
Page: 1-14
PDF size: 420.17 Kb.


ABSTRACT

Introduction: Rapid desensitization to drugs induces a temporary tolerance to chemotherapeutics causing hypersensitivity reactions.
Objective: To evaluate the rapid desensitization protocol in an outpatient setting in patients who had hypersensitivity reactions to cytotoxic drugs.
Methods: An observational and retrospective study was carried out in 30 cancer patients, who developed hypersensitivity reactions, from 2016 to 2018. They were treated in the outpatient Oncology service at Hermanos Ameijeiras Surgical Clinical Hospital. These subjects were classified according to intensity; demographic variables, clinical characteristics, and symptoms were analyzed. A twelve-step protocol based on three dilutions of the drug was used. Premedication was administered in all cases. Descriptive statistics and for the association between variables were performed. Chi-square statistical test was used.
Results: The median age was 54 years (23; 77). Predominance was observed in women, those under 60 years of age, primary colon tumor, history of allergy, oxaliplatin as the drug most implicated, HRH during infusion, and moderate intensity. Skin and gastrointestinal symptoms were more frequent. The planned chemotherapy was completed with the application of the protocol, in all 30 patients (145 additional cycles). There were only eight desensitization with mild skin-type reactions. 94.5% of desensitizations did not show any reaction.
Conclusions: It constitutes the first national report of successful use of a rapid desensitization protocol to cytostatics that proved to be effective and safe in the outpatient setting with multidisciplinary management.


REFERENCES

  1. Pradelli J, Verdoire P, Boutros J, Frin AC, Follana P, Duquesne J, et al. Allergy evaluation of hypersensitivity to platinium salts and taxanes: a six-year experience. J Allergy Clin Immunol Pract. 2020;8(5):1658-64. https://doi.org/10.1016/j.jaip.2019.12.032

  2. O'Malley DM, Vetter MH, Cohn DE, Khan A, Hays JL. Outpatient desensitization in selected patients with platinum hypersensitivity reactions. Gynecol Oncol. 2017;145(3):603-10. http://dx.doi.org/10.1016/j.ygyno.2017.03.015

  3. US Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE). Version 5.0. 2017[acceso: 15/07/2020]. Disponible en: https://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf

  4. National Comprehensive Cancer Network. Ovarian cancer (version 2.2020). 2020[acceso: 15/07/2020]. Disponible en: https://www.nccn.org/professionals/physician_gls/pdf/ovarian.pdf

  5. Muallaoglu S, Disel U, Mertsoylu H, Besen A, Karadeniz C, Sumbul AT, et al. Acute infusion reaction to chemotherapeutic drugs: a single institute experience. J BUON. 2013;18:261-67.

  6. Bonamichi-Santos R, Castells M. Diagnoses and management of drug hypersensitivity and anaphylaxis in cancer and chronic inflammatory diseases: reactions to taxanes and monoclonal antibodies. Clin Rev Allergy Immunol. 2018;54(3):375-85. https://doi.org/10.1007/s12016-016-8556-5

  7. Schrijvers R, Gilissen L, Chiriac AM, Demoly P. Pathogenesis and diagnosis of delayed-type drug hypersensitivity reactions from bedside to bench and back. Clin Transl Allergy. 2015;5:31. https://doi.org/10.1186/s13601-015-0073-8

  8. Mori F, Saretta F, Bianchi A, Crisafulli G, Caimmi S, Liotti L, et al. Hypersensitivity reactions to monoclonal antibodies in children. Medicina. 2020;56:232. https://doi.org/10.3390/medicina56050232

  9. Lee CW, Matulonis UA, Castells MC. Carboplatin hypersensitivity: a 6-h 12-step protocol effective in 35 desensitizations in patients with gynecological malignancies and mast cell/IgE-mediated reactions. Gynecol Oncol. 2004;95:370-76. https://doi.org/10.1016/j.ygyno.2004.08.002

  10. Castells MC, Tennant NM, Sloane DE, Hsu FI, Barrett NA, Hong DI, et al. Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases. J Allergy Clin Immunol. 2008;122:574-80. https://doi.org/10.1016/j.jaci.2008.02.044

  11. Castells M. Drug hypersensitivity and anaphylaxis in cancer and chronic inflammatory diseases: the role of desensitizations. Front Immunol. 2017;8:1472. https://doi.org/10.3389/fimmu.2017.01472

  12. de Las Vecillas Sánchez L, Alenazy LA, Garcia-Neuer M, Castells MC. Drug hypersensitivity and desensitizations: mechanisms and new approaches. Int J Mol Sci. 2017;18(6):1316. https://doi.org/10.3390/ijms18061316

  13. Mach CM, Lapp EA, Weddle KJ, Hunter RJ, Burns KA, Parker C, et al. Adjunct histamine blockers as premedications to prevent carboplatin hypersensitivity reactions. Pharmacotherapy. 2016;36(5):482-87. https://doi.org/10.1002/phar.1739

  14. Jerzak KJ, Deghan Manshadi S, Ng P, Maganti M, McCuaig JM, Bulter M, et al. Prevention of carboplatin-induced hypersensitivity reactions in women with ovarian cancer. J Oncol Pharm Pract. 2018;24(2):83-90. https://doi.org/10.1177/1078155216679028

  15. Picard M, Castells MC. Re-visiting hypersensitivity reactions to Taxanes: a comprehensive review. Clin Rev Allergy Immunol. 2015;49(2):177-91. https://doi.org/10.1007/s12016-014-8416-0

  16. Caiado J, Castells M. Presentation and diagnosis of hypersensitvitiy to platinum drugs. Curr Allergy Asthma Rep. 2015;15(4):15. https://doi.org/10.1007/s11882-015-0515-3

  17. Parel M, Ranchon F, Nosbaum A, You B, Vantard N, Schwiertz V, et al. Hypersensitivity to oxaliplatin: clinical features and risk factors. BMC Pharmacol Toxicol. 2014;15:1. https://doi.org/10.1186/2050-6511-15-1

  18. Okayama T, Ishikawa T, Sugatani K, Yoshida N, Kokura S, Matsuda K, et al. Hypersensitivity reactions to oxaliplatin: identifying the risk factors and judging the efficacy of a desensitization protocol. Clin Ther. 2015;37(6):1259-69. https://doi.org/10.1016/j.clinthera.2015.03.012

  19. Markman M, Zanotti K, Kulp B, Peterson G, Markman M. Relationship between a history of systemic allergic reactions and risk of subsequent carboplatin hypersensitivity. Gynecol Oncol. 2003;89(3):514-16. https://doi.org/10.1016/s0090-8258(03)00155-0

  20. Roselló S, Blasco I, García Fabregat L, Cervantes A, Jordan K. Management of infusion reactions to systemic anticancer therapy: ESMO Clinical Practice Guidelines. Ann Oncol. 2017;1(28):100-18. https://doi.org/10.1093/annonc/mdx216

  21. DeMoor PA, Matusov Y, Kelly C, Olan S, Barnachea L, Bazhenova LA. A retrospective review of the frequency and nature of acute hypersensitivity reactions at a medium-sized infusion center: comparison to reported values and inconsistencies. J Cancer. 2011;2:153-64. https://doi.org/10.7150/jca.2.153

  22. Kendirlinan R, Gümüsburun R, Çerçi P, Özbek E, Altiner S, Çelebi Sözener Z, et al. Rapid drug desensitization with chemotherapeutics (platins, taxanes, and others): a single-center retrospective study. Int Arch Allergy Immunol. 2019;179(2):114-22. https://doi.org/10.1159/000496745

  23. Makrilia N, Syrigou E, Kaklamanos I, Manolopoulos L, Saif MW. Hypersensitivity reactions associated with platinum antineoplastic agents: a systematic review. Met Based Drugs. 2010[acceso: 20/06/2020];207084. Disponible en: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2945654/pdf/MBD2010-207084.pdf

  24. Mawhirt SL, Fonacier LS, Calixte R, Davis-Lorton M, Aquino MR. Skin testing and desensitization outcomes among platinum-sensitive oncology patients. Ann Allergy Asthma Immunol. 2018;120:437-39. https://doi.org/10.1016/j.anai.2018.01.008

  25. Brault F, Waton J, Poreaux C, Schmutz JL, Barbaud A. Hypersensibilité aux sels de platine et aux taxanes: intérêt des tests cutanés et desinductions de tolerance. Ann Dermatol Venereol. 2017;144(11):685-95. https://doi.org/10.1016/j.annder.2017.05.016

  26. Takase N, Matsumoto K, Onoe T, Kitao A, Tanioka M, Kikukawa Y, et al. 4-step 4-h carboplatin desensitization protocol for patients with gynecological malignancies showing platinum hypersensitivity: a retrospective study. Int J Clin Oncol. 2015;20(3):566-73. https://doi.org/10.1007/s10147-014-0731-1

  27. Chung SJ, Kang SY, Kang RY, Kim YC, Lee KH, Kim TY, et al. A new non-dilution rapid desensitization protocol successfully applied to all-grade platinum hypersensitivity. Cancer Chemother Pharmacol. 2018;82(5):777-85. https://doi.org/10.1007/s00280-018-3662-0

  28. Vetter MH, Khan A, Backes FJ, Bixel K, Cohn DE, Copeland LJ, et al. Outpatient desensitization of patients with moderate (high-risk) to severe platinum hypersensitivity reactions. Gynecol Oncol. 2019;152(2):316-21. https://doi.org/10.1016/j.ygyno.2018.10.037

  29. Sloane D, Govindarajulu U, Harrow-Mortelliti J, Barry W, Hsu FI, Hong D, et al. Safety, costs, and efficacy of rapid drug desensitizations to chemotherapy and monoclonal antibodies. J Allergy Clin Immunol Pract. 2016;4:497-504. https://doi.org/10.1016/j.jaip.2015.12.019

  30. Brockow K, Schallmayer S, Beyer K Biedermann T, Fischer J, Gebert N, et al. Effects of a structured educational intervention on knowledge and emergency management in patients at risk for anaphylaxis. Allergy. 2015;70:227-35. https://doi.org/10.1111/all.12548




2020     |     www.medigraphic.com